About MDA

Fighting every day to free individuals — and the families who love them — from the harmful effects of muscle-debilitating diseases so they can live longer and grow stronger

Press Releases

  • Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for Patients with Duchenne Muscular Dystrophy (DMD)

    Patients Can Now Receive Deflazacort, an Investigational Treatment from Marathon, at No Cost Through Medical Research Centers Across U.S.

    Full Press Release: http://www.prnewswire.com/news-releases/marathon-pharmaceuticals-announc...

  • MDA Shamrocks Help Fight Muscular Dystrophy

    CHICAGO, March 1, 2016— Tens of thousands of retailers nationwide have rallied together to raise funds to help the Muscular Dystrophy Association (MDA) save and improve the lives of kids and adults with muscular dystrophy, ALS and related life-threatening diseases that severely weaken muscle strength and mobility by participating in the 34th annual MDA Shamrocks program —the nation’s largest St. Patrick's Day fundraising program of its kind.

  • FAQ – Eteplirsen for DMD

    The experimental drug eteplirsen, under development by Sarepta Therapeutics to treat Duchenne muscular dystrophy (DMD), is under review by the U.S. Food and Drug Administration (FDA) for market approval. It marks an exciting and historic time for the MDA community and an important milestone for DMD treatments. Before a final decision is rendered, however, an FDA Advisory Committee will review the drug and provide a recommendation to the regulatory agency.

  • FDA Tells PTC Therapeutics That Ataluren (Translarna) Is Not Ready For Review At This Time

    Background: PTC Therapeutics today announced that it received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) regarding PTC’s New Drug Application (NDA) for ataluren (brand name Translarna) to treat Duchenne muscular dystrophy (DMD).

    In the letter, the FDA states that the application was not sufficiently complete to permit a substantive review. PTC is reviewing the content of the letter to determine the appropriate next steps.

  • Lowe’s Supports MDA Shamrocks Program and Summer Camps to Help Families and Children with Muscular Dystrophy

    CHICAGO, Feb. 16, 2016 — Lowe’s stores nationwide unite to participate in the Muscular Dystrophy Association’s iconic Shamrocks program now through March 31. This year marks 15 years of Lowe’s Shamrocks support that helps improve lives in communities across the country and build stronger futures for kids and adults with muscular dystrophy, ALS and related life-threatening diseases that severely weaken muscle strength and mobility.

  • MDA Awards $11 Million in New Research Grants

    CHICAGO, February 11, 2016 – After a historic unveiling of a revitalized rebranding in January, MDA today announced the award of 41 new research, development and research infrastructure grants totaling nearly $11 million and covering 13 different diseases.